412944-46-8

Basic information

• Product Name: Benzoic acid, 4-bromo-3-methyl-5-nitro-, methyl ester
• CAS NO: 412944-46-8
• Molecular Formula: C9H8BrNO4
• Molecular Weight: 274.071
• Mol File: 412944-46-8.mol

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 4-bromo-3-methyl-5-nitro-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-bromo-3-methyl-5-nitro-, methyl ester(412944-46-8)
• EPA Substance Registry System: Benzoic acid, 4-bromo-3-methyl-5-nitro-, methyl ester(412944-46-8)

Safety Data

• Hazardous Substances Data: 412944-46-8(Hazardous Substances Data)

Upstream product

• 148547-19-7 4-Bromo-3-methylbenzoic acid methyl ester 
• 854627-73-9 4-bromo-3-methyl-5-nitrobenzonitrile 
• 6933-10-4 amino-5-bromo-2-toluene 
• 41963-20-6 4-bromo-3-methylbenzonirtile 

Downstream Products

• 408533-82-4 4-bromo-3-methyl-5-nitro-benzoic acid 
• 631911-29-0 6-(3-{4-amino-3'-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-yl}-ureido)-hexanoic acid 
• 631911-93-8 {2-amino-3'-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-4-yl}-carbamic acid 2-trimethylsilanyl-ethyl ester 
• 631911-92-7 [3-amino-5-methyl-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-carbamic acid 2-trimethylsilanyl-ethyl ester 
• 631911-91-6 (3-amino-4-bromo-5-methyl-phenyl)-carbamic acid 2-trimethylsilanyl-ethyl ester 
• 631911-90-5 (4-bromo-3-methyl-5-nitro-phenyl)-carbamic acid 2-trimethylsilanyl-ethyl ester 
• 631911-27-8 6-{3-[3'-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-4-(2-trimethylsilanyl-ethoxycarbonylamino)-biphenyl-2-yl]-ureido}-hexanoic acid ethyl ester 

Relevant articles and documents

HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS

ABSTRACT The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.

Conjugated complement cascade inhibitors

The present invention is directed to conjugated complement cascade inhibitors, and a method of treating a patient using a conjugated complement cascade inhibitor.

Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions

Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4 and R7 are defined in the specification, Z is SO or SO2, and Ar is an aromatic or heteroaromatic group as defined herein.

NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS

Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula (I) or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4 and R7 are defined in the specification, Z is SO or SO2, and Ar is an aromatic or heteroaromatic group as defined herein.